TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26643109
Drug: Pollen extract
Normalized name: pollen extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pollen extract (Cernilton) (two capsules, q 8 h) for 8 weeks
Study: 18440315
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of immunosuppressives (Dis)
Study: 2865148
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg (single dose)
Study: 2865148
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg (single dose)
Study: 2865148
Drug: Propranolol 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 320 mg (single dose)
Study: 2865148
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg (chronic administration for 7 days)
Study: 2865148
Drug: Nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 80 mg (chronic administration for 7 days)
Study: 2865148
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (chronic administration for 7 days)
Study: 31228861
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion system (CIIS)
Study: 31228861
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin administrations (MDI)
Study: 29727385
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine L-aspartate (LOLA) 6g thrice daily
Study: 26649938
Drug: High-dose prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prolonged magnesium sulfate infusion (50 mg/kg/hr for 4 hours)
Study: 26649938
Drug: Bolus magnesium
Normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus magnesium sulfate (50 mg/kg over 1 hour)
Study: 26649938
Drug: High-dose prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prolonged magnesium sulfate infusion
Study: 24506775
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate ophthalmic solution 0.2% administered three times a day for 1 day
Study: 24506775
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate gel 0.07% applied twice daily for 29 days
Study: 24506775
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate gel 0.18% applied once daily for 29 days
Study: 24506775
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate gel 0.18% applied twice daily for 29 days
Study: 24506775
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate gel 0.5% applied once daily for 29 days
Study: 22686073
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg/d) in the Western medicine group (WM)
Study: 22686073
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine treatment by syndrome typing in the Chinese medicine group (CM)
Study: 22686073
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Benazepril and Chinese herbs in the combination group
Study: 20511580
Drug: Telephone booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone booster intervention (weekly reinforcement of clinic advice)
Study: 17606976
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of relapse after EF-RT
Study: 12131112
Drug: AMR 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR 15 group (15 microg x kg(‐1) x min(‐1) amrinone with a 1.0‐mg/kg loading dose)
Study: 12131112
Drug: ReAMR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReAMR group (5 microg x kg(‐1) x min(‐1) amrinone with 1.0‐mg/kg loading and reloading doses)
Study: 10343521
Drug: Sulphasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine (SSZ) 2-3 g/day
Study: 10343521
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5-15 mg/week
Study: 10343521
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sulphasalazine and Methotrexate (COMBI) same dose range as above
Study: 7856896
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (50-100 micrograms)
Study: 1974395
Drug: Priming with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priming with vecuronium (0.01 mg/kg priming dose, 4‐min priming interval, 0.14‐mg/kg intubating dose along with thiopental 4‐6 mg iv)
Study: 1974395
Drug: Timing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing with vecuronium (0.15‐mg/kg intubating dose given before thiopental and timed to weakness of hand grip)
Study: 31929136
Drug: Modality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modality treatment (Control)
Study: 25238492
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/d
Study: 24104790
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (10 mg tablet orally up to five doses)
Study: 24104790
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (escalating doses of 20, 40, 80, 80, and 80 mg)
Study: 21221853
Drug: Panitumumab-based therapy
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab-based therapy (PBT)
Study: 18413818
Drug: Aspirin exposure
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin exposure with ODC 316AA genotype
Study: 18413818
Drug: Aspirin exposure
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin exposure with homozygous ODC 316AA genotype
Study: 18413818
Drug: Aspirin exposure
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin exposure with wild-type or heterozygous genotypes
Study: 18413818
Drug: Aspirin exposure
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin exposure with both ODC 316AA genotype
Study: 12213665
Drug: Saturated solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated solution of potassium iodide (SSKI) for 10-15 days
Study: 9828818
Drug: Immunohistochemistry using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemistry using HMB‐45 antibody
Study: 2696850
Drug: R 76713
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 76713 (5 mg)
Study: 2696850
Drug: R 76713
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 76713 (10 mg)
Study: 2696850
Drug: R 76713
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 76713 (20 mg)
Study: 4887385
Drug: Phenformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenformin (up to 300 mg daily)
Study: 4887385
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 3 g daily)
Study: 4887385
Drug: Phenformin and
Normalized name: phenformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenformin and Metformin (combined)
Study: 26769303
Drug: MK‐8389 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐8389 (oral doses once daily for 14 days)
Study: 26769303
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral doses once daily for 14 days)
Study: 21947316
Drug: D: ‐amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D: ‐amphetamine 10 mg
Study: 21947316
Drug: D: ‐amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D: ‐amphetamine 20 mg
Study: 15222054
Drug: Glutamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (30 g/d for 7 days)
Study: 15222054
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 g/d for 7 days)
Study: 1978470
Drug: Remoxipride 75-300
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride 75-300 mg twice daily
Study: 1978470
Drug: Haloperidol 5-20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5-20 mg twice daily
Study: 27886407
Drug: PRX002 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX002 (0.3, 1, 3, 10, or 30 mg/kg)
Study: 23325325
Drug: Davunetide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Davunetide (5 and 30 mg/day)
Study: 21876641
Drug: Imiquimod 3.75%
Normalized name: IMIQUIMOD 3.75% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 3.75% cream applied daily until complete clearance or a maximum of 8 weeks
Study: 21876641
Drug: Imiquimod 2.5%
Normalized name: IMIQUIMOD 2.5% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 2.5% cream applied daily until complete clearance or a maximum of 8 weeks
Study: 21876641
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied daily until complete clearance or a maximum of 8 weeks
Study: 19570991
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aerobic plus resistance exercise (HAC)
Study: 14981868
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification including changes in diet and activity; no specific dosage or duration mentioned.
Study: 14981868
Drug: Pharmacotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy or surgery; details not specified.
Study: 9713266
Drug: Amenorrhoea after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amenorrhoea after adjuvant chemotherapy
Study: 7978210
Drug: Lignocaine cardioplegia
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine cardioplegia (100 mg/l)
Study: 2730828
Drug: Nicardipine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine infusion
Study: 779298
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate preparation (control)
Study: 30454850
Drug: SMEDS formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMEDS formulation (500 mg EPA + DHA)
Study: 30454850
Drug: Standard ω-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ω-3 acid EE formulation (840 mg EPA + DHA)
Study: 30454850
Drug: SMEDS formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMEDS formulation
Study: 26242295
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of vitamin D (100,000 IU on day 1, then 2 and 4 weeks after surgery) followed by maintenance dose (3420 IU/day)
Study: 26242295
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by standard dose of vitamin D (3420 IU/day)
Study: 23855173
Drug: No pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pretreatment (Control) + various bonding agents
Study: 20883428
Drug: PAC (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC (pantoprazole 40 mg b.i.d., amoxicillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d. for 7 days)
Study: 20883428
Drug: PBMT (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT (pantoprazole 40 mg b.i.d., colloidal bismuth subcitrate 220 mg b.i.d, metronidazole 400 mg t.i.d., tetracycline 750 mg b.i.d. for 10 days)
Study: 12969999
Drug: Inhaled flunisolide
Normalized name: flunisolide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled flunisolide (ICS), 1 mg, four inhalations bid for 7 days
Study: 12969999
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (OCS), 2 mg/kg (max 60 mg/d) for 7 days
Study: 1881720
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (Ig) therapy
Study: 7055176
Drug: Tetracycline, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline, 500 mg, four times daily for 7 days
Study: 7055176
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg, four times daily for 7 days
Study: 7055176
Drug: Erythromycin, 250
Normalized name: Erythromycin, 250 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 250 mg, four times daily for 7 days
Study: 7055176
Drug: Tetracycline, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline, 500 mg, four times daily for 10 days
Study: 7055176
Drug: Sulfisoxazole, 500
Normalized name: SulfiSOXAZOLE, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfisoxazole, 500 mg, four times daily for 10 days
Study: 7055176
Drug: Ampicillin, loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, loading dose plus additional ampicillin for 3 to 21 days
Study: 23689765
Drug: Oxandrolone, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone, 20 mg/d (n = 108)
Study: 19880676
Drug: CP-690,550 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 5 mg bid
Study: 19880676
Drug: CP-690,550 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 15 mg bid
Study: 19880676
Drug: CP-690,550 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 30 mg bid
Study: 18591750
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (specific dosage and duration not mentioned)
Study: 16616745
Drug: Serum anti-müllerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum anti-müllerian hormone (AMH) levels in patients with premature ovarian failure (POF)
Study: 16616745
Drug: Serum anti-müllerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum anti-müllerian hormone (AMH) levels in patients with polycystic ovary syndrome (PCOS)
Study: 8858270
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg (evening dose)
Study: 8858270
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg (morning dose)
Study: 1532974
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy for induction of remission
Study: 8099363
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy for maintenance of remission at 6 months
Study: 8099363
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy for maintenance of remission at 12 months
Study: 3548009
Drug: Meperidine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 80 mg
Study: 3548009
Drug: Butorphanol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (4 mg) vs Meperidine (80 mg)
Study: 24011464
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy on one side of the jaw
Study: 19956085
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg DMXB-A
Study: 19956085
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg DMXB-A
Study: 15895328
Drug: Function-centered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Function-centered treatment (FCT) (4h/d, 6d/wk, for 3 wk)
Study: 15895328
Drug: Pain-centered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-centered treatment (PCT) (2.5h/d, 6d/wk, for 3 wk)
Study: 6391504
Drug: Praziquantel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (25 mg per kg of body weight, 3 times daily for one or two days)
Study: 6391504
Drug: Praziquantel (two-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (two-day dosage schedule)
Study: 6391504
Drug: Praziquantel (one-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (one-day dosage schedule)
Study: 31775808
Drug: Intra-substance injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-substance injection with Diprospan (1 cc) and 1% xylocaine (1 cc)
Study: 31775808
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 cc) and 1% xylocaine (1 cc)
Study: 30572588
Drug: Daily substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily substitution of one portion of red meat with white meat, oily fish or white fish
Study: 22791755
Drug: Low-dose pioglitazone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Study: 16954331
Drug: Intravenous microdialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous microdialysis of N(G)-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor) during local warming to 42 degrees C
Study: 11914932
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg NSC‐631570
Study: 11914932
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg gemcitabine/m2 followed by 20 mg NSC‐631570 weekly
Study: 11914932
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg gemcitabine/m2
Study: 1320917
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron 1.0 mg twice daily
Study: 1320917
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron 0.25 mg twice daily
Study: 1320917
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron 0.5 mg twice daily
Study: 31470240
Drug: ECIG+OB (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECIG+OB (18 ng/ml nicotine)
Study: 29756979
Drug: Glutamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (10 g every 8 hours)
Study: 25091553
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion with standard treatment
Study: 17623016
Drug: Indomethacin plus
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin plus statin (10 mg of rosuvastatin)
Study: 26982282
Drug: Cream
Normalized name: Cream
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream
Study: 26060395
Drug: Dressing Gel
Normalized name: RADIAGEL WOUND DRESSING GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing Gel
Study: 15122540
Drug: Piribedil (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (150 mg mean daily dose)
Study: 9269062
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose at 24 weeks
Study: 3087091
Drug: Clenbuterol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenbuterol (3 X 0.02 mg/d)
Study: 24158846
Drug: Intracameral bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intracameral bevacizumab (1.25 mg, 50 µL)
Study: 24158846
Drug: Placebo (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (balanced salt solution, 50 µL)
Study: 23107655
Drug: n-3PUFA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3PUFA (1 g/day)
Study: 19593146
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with remifentanil and propofol (group TIVA)
Study: 1890744
Drug: HLBI-VCAP (II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLBI-VCAP (II) regimen (HLBI 3 x 10(6) units/day, twice a week)
Study: 1890744
Drug: HLBI-VCAP (I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLBI-VCAP (I) regimen (HLBI 3 x 10(6) units/day, daily, 56 days)
Study: 28264833
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment (AC)
Study: 19124057
Drug: PRP-OMPC formulations
Normalized name: NEISSERIA MENINGITIDIS OMPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-OMPC formulations (3microg or 6microg)
Study: 19124057
Drug: PRP-T formulation
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T formulation (12microg)
Study: 19124057
Drug: PRP-OMPC formulations
Normalized name: NEISSERIA MENINGITIDIS OMPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-OMPC formulations
Study: 19124057
Drug: PRP-OMPC formulation
Normalized name: NEISSERIA MENINGITIDIS OMPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-OMPC formulation with the lowest concentration
Study: 12020983
Drug: 17beta‐estradiol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 2 mg+norethisterone acetate 1mg (E2+NETA) daily
Study: 12020983
Drug: Raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCl 60 mg (Evista) daily
Study: 11783305
Drug: Juanxiao Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juanxiao Tablet (JXT)